ArticleBMC surgery2025
Preoperative risk model and nomogram for 30‑Day mortality after TAVR: development and internal validation in a Chinese cohort.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAccurate prediction of 30‑day mortality after transcatheter aortic valve replacement (TAVR) remains challenging. Existing models often overlook key preoperative laboratory variables. We aimed to develop and internally validate a preoperative risk prediction model using routinely available variables measured before the procedure.We state that predictors were preoperative‑only.
methodsWe retrospectively analyzed 1,673 consecutive patients who underwent TAVR at Fuwai Hospital between 2013 and 2023. Patients were randomly split into a training cohort (n = 1,171) and an internal hold out validation cohort (n = 502). Candidate predictors were prespecified as routinely available preoperative variables. All candidate predictors, including laboratory parameters (troponin, D‑dimer, HbA1c, uric acid, etc.), were collected during the preoperative evaluation, within 3 days prior to the TAVR procedure. Independent predictors of 30-day mortality were identified using multivariable logistic regression. Performance was assessed with receiver operating characteristic (ROC) analysis, calibration assessment (calibration plots and Hosmer Lemeshow test), and bootstrap optimism correction; a nomogram was constructed from the final model.
results30-day mortality was 3.4% in both the training (40/1,171) and validation (17/502) cohorts. The final preoperative model retained STS score, HbA1c, D-dimer, and uric acid as independent predictors. Discrimination was good (AUC=0.84 in the training cohort; AUC=0.78 in the internal validation cohort), with acceptable calibration (Hosmer-Lemeshow p = 0.211); optimism corrected performance closely matched the hold out out results. The resulting nomogram provides individualized risk estimates for 30-day mortality based on these preoperative predictors.
conclusionsWe developed and internally validated a parsimonious preoperative risk model and nomogram for 30-day mortality after TAVR using routinely available clinical and laboratory variables. This tool may support individualized risk stratification in elective/non salvage TAVR candidates. External validation particularly beyond East-Asian populations is essential before broader application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.